Physician profile
Aney Paul
NPI 1700118627
$1,838.88
in general payments reported to CMS, 2019-2025
12 companies · $614 in 2025
The $614 reported for 2025 was more than what 94% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $388 · 2023: $100 · 2024: $632 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.48 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $341.69 | 2024 | Fasenra, Tezspire, Calquence |
| Medical Device Business Services, INC. | $287.00 | 2025 | Dermabond |
| Genzyme Corporation | $191.90 | 2022-2025 | |
| Boston Scientific Corporation | $148.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.99 | 2025 | Cobenfy |
| Ucb, INC. | $125.00 | 2025 | Nayzilam |
| Ani Pharmaceuticals, INC. | $125.00 | 2024 | Purified Cortrophin Gel |
| Corcept Therapeutics | $115.00 | 2022 | |
| Neurelis, INC. | $104.18 | 2024 | Valtoco |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $104.02 | 2021 | |
| Mallinckrodt Hospital Products INC. | $100.00 | 2023 | Terlivaz |
| Axonics, INC. | $61.54 | 2024 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aney Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.